Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H30NO3.Br |
Molecular Weight | 448.393 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].CC[N+]3(CCOC(=O)C(O)(C1=CC=CC=C1)C2=CC=CC=C2)CCCCC3
InChI
InChIKey=VPUGSHLBERYQGC-UHFFFAOYSA-M
InChI=1S/C23H30NO3.BrH/c1-2-24(16-10-5-11-17-24)18-19-27-22(25)23(26,20-12-6-3-7-13-20)21-14-8-4-9-15-21;/h3-4,6-9,12-15,26H,2,5,10-11,16-19H2,1H3;1H/q+1;/p-1
Molecular Formula | C23H29NO3 |
Molecular Weight | 367.4813 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | BrH |
Molecular Weight | 80.912 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugs.com/international/pipethanate-ethobromide.html | http://www.druginfosys.com/drug.aspx?drugcode=2164&type=1 | https://www.ncbi.nlm.nih.gov/pubmed/5170094 | http://www.rjbc.ru/arc/11/10/1402-1416.pdf | https://www.ncbi.nlm.nih.gov/pubmed/5170093
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/pipethanate-ethobromide.html | http://www.druginfosys.com/drug.aspx?drugcode=2164&type=1 | https://www.ncbi.nlm.nih.gov/pubmed/5170094 | http://www.rjbc.ru/arc/11/10/1402-1416.pdf | https://www.ncbi.nlm.nih.gov/pubmed/5170093
Pipethanate ethobromide is an antimuscarinic with actions similar to those of atropine. It has been used in the symptomatic treatment of visceral spasms in oral doses of up to 160 mg daily in divided doses. Pipethanate ethobromide has also been given intramuscularly or intravenously in doses of 10 to 20 mg daily and rectally in doses of 60 or 120 mg daily.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094109 Sources: http://www.rjbc.ru/arc/11/10/1402-1416.pdf |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Epithanate G Approved UseUnknown |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:15:27 GMT 2023
by
admin
on
Sat Dec 16 07:15:27 GMT 2023
|
Record UNII |
ZA38L5WD1K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ZA38L5WD1K
Created by
admin on Sat Dec 16 07:15:27 GMT 2023 , Edited by admin on Sat Dec 16 07:15:27 GMT 2023
|
PRIMARY | |||
|
100000090458
Created by
admin on Sat Dec 16 07:15:27 GMT 2023 , Edited by admin on Sat Dec 16 07:15:27 GMT 2023
|
PRIMARY | |||
|
DTXSID7046677
Created by
admin on Sat Dec 16 07:15:27 GMT 2023 , Edited by admin on Sat Dec 16 07:15:27 GMT 2023
|
PRIMARY | |||
|
23182-46-9
Created by
admin on Sat Dec 16 07:15:27 GMT 2023 , Edited by admin on Sat Dec 16 07:15:27 GMT 2023
|
PRIMARY | |||
|
m8853
Created by
admin on Sat Dec 16 07:15:27 GMT 2023 , Edited by admin on Sat Dec 16 07:15:27 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB03856MIG
Created by
admin on Sat Dec 16 07:15:27 GMT 2023 , Edited by admin on Sat Dec 16 07:15:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL1722893
Created by
admin on Sat Dec 16 07:15:27 GMT 2023 , Edited by admin on Sat Dec 16 07:15:27 GMT 2023
|
PRIMARY | |||
|
168088
Created by
admin on Sat Dec 16 07:15:27 GMT 2023 , Edited by admin on Sat Dec 16 07:15:27 GMT 2023
|
PRIMARY |